phrykt

Enliven Therapeutics, Inc. (ELVN): who owns it and who trades it

As of Nov 16, 2026, ELVN insiders reported 74 open-market sales worth $76.7M and no purchases in the last 12 months, with 31% of the sale value made under pre-set 10b5-1 plans. The largest seller was Orbimed Advisors Llc (10% owner), with $51.7M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Enliven Therapeutics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ELVN

211 funds and institutions reported ELVN shares worth $4.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 16.5%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

FMR LLC (Fidelity)16.5%
Orbimed Advisors LLC11.1%
Polar Capital Holdings Plc10.6%
BlackRock, Inc.7.2%
Vestal Point Capital, LP6.6%
Commodore Capital LP5.4%
T. Rowe Price Associates4.8%
California State Teachers Retirement System4.4%
Vanguard Capital Management LLC4.2%
Citadel Advisors LLC3.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)10.03M16.46%$509M+47%
Orbimed Advisors LLC6.78M11.13%$344M-15%
Polar Capital Holdings Plc6.43M10.56%$326M+27%
BlackRock, Inc.4.36M7.16%$221M+18%
Vestal Point Capital, LP4.00M6.57%$203M+23%
Commodore Capital LP3.27M5.38%$166MNo change
T. Rowe Price Associates2.90M4.77%$147M+2871%
California State Teachers Retirement System2.71M4.44%$53.3M+8378%
Vanguard Capital Management LLC2.57M4.22%$130M+18%
Citadel Advisors LLC2.07M3.40%$105M+19%
Fairmount Funds Management LLC1.86M3.05%$94.2MNo change
Siren, L.L.C.1.77M2.91%$90.1M+138%
Bellevue Group AG1.49M2.45%$75.6M-36%
Geode Capital Management, LLC1.41M2.31%$71.4M+32%
First Light Asset Management, LLC1.36M2.23%$69.1M+574%
State Street Corp1.21M1.99%$61.6M+11%
Pictet Asset Management Holding SA1.16M1.91%$59M+25%
Adage Capital Partners Gp, L.l.c.1.08M1.78%$55M–
Novo Holdings A/s1.00M1.64%$50.8M-22%
First Turn Management, LLC954,3601.57%$48.4M+53%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ELVN insiders reported $0 of open-market purchases and $76.7M of sales. 31% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$76.7M
74 trades, 10 people
Sales under a 10b5-1 plan
31%
Share of sale value
Latest trade
Oct 19, 2026
Filed Oct 21, 2026

Purchases and sales by month

$52.5M$52.5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 19, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan5,000$38.47$192KForm 4
Oct 19, 2026Benjamin HohlCFOSale plan6,018$38.48$232KForm 4
Oct 1, 2026J. Scott GarlandDirectorSale13,000$46.67$607KForm 4
Sep 17, 2026Benjamin HohlCFOSale plan3,535$50.03$177KForm 4
Sep 17, 2026Benjamin HohlCFOSale plan2,194$50.72$111KForm 4
Sep 17, 2026Benjamin HohlCFOSale plan289$51.49$14.9KForm 4
Sep 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan1,844$50.71$93.5KForm 4
Sep 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,916$50.03$146KForm 4
Sep 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan240$51.48$12.4KForm 4
Aug 17, 2026Benjamin HohlCFOSale plan4,630$58.35$270KForm 4
Aug 17, 2026Benjamin HohlCFOSale plan1,388$59.35$82.4KForm 4
Aug 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan3,900$58.37$228KForm 4
Aug 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan1,100$59.35$65.3KForm 4
Aug 4, 2026Mika K DerynckDirectorSale plan158,795$60.21$9.6MForm 4
Jul 17, 2026Benjamin HohlCFOSale plan123$53.87$6.6KForm 4
Jul 17, 2026Benjamin HohlCFOSale plan2,638$53.38$141KForm 4
Jul 17, 2026Benjamin HohlCFOSale plan324$49.97$16.2KForm 4
Jul 17, 2026Benjamin HohlCFOSale plan369$51.48$19KForm 4
Jul 17, 2026Benjamin HohlCFOSale plan2,564$52.32$134KForm 4
Jul 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,063$52.39$108KForm 4
Jul 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,184$53.42$117KForm 4
Jul 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan63$53.92$3.4KForm 4
Jul 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan231$50.05$11.6KForm 4
Jul 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan459$51.55$23.7KForm 4
Jul 6, 2026Lori Anne KunkelDirectorSale plan5,889$50.84$299KForm 4
Jul 6, 2026Lori Anne KunkelDirectorSale plan4,111$49.98$205KForm 4
Jun 22, 2026Orbimed Advisors Llc +210% ownerSale24,846$45.38$1.1MForm 4
Jun 22, 2026Orbimed Advisors Llc +210% ownerSale46,776$45.00$2.1MForm 4
Jun 22, 2026Orbimed Advisors Llc +210% ownerSale787,024$45.38$35.7MForm 4
Jun 22, 2026Orbimed Advisors Llc +210% ownerSale1,477$45.00$66.5KForm 4
Jun 17, 2026Benjamin HohlCFOSale plan1,238$44.75$55.4KForm 4
Jun 17, 2026Benjamin HohlCFOSale plan3,401$43.86$149KForm 4
Jun 17, 2026Benjamin HohlCFOSale plan1,379$42.79$59KForm 4
Jun 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan1,268$42.83$54.3KForm 4
Jun 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,599$43.87$114KForm 4
Jun 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan1,133$44.74$50.7KForm 4
Jun 15, 2026Orbimed Advisors Llc +210% ownerSale9,086$45.02$409KForm 4
Jun 15, 2026Orbimed Advisors Llc +210% ownerSale272,322$45.02$12.3MForm 4
Jun 5, 2026Lori Anne KunkelDirectorSale plan354$35.82$12.7KForm 4
Jun 5, 2026Lori Anne KunkelDirectorSale plan7,779$34.28$267KForm 4
Jun 5, 2026Lori Anne KunkelDirectorSale plan1,867$35.36$66KForm 4
May 18, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan1,302$40.25$52.4KForm 4
May 18, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan3,475$39.53$137KForm 4
May 18, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan223$41.21$9.2KForm 4
Apr 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,441$48.06$117KForm 4
Apr 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan140$45.81$6.4KForm 4
Apr 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan2,419$47.39$115KForm 4
Mar 25, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan40,000$35.10$1.4MForm 4
Mar 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan5,000$27.76$139KForm 4
Mar 10, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan10,129$30.19$306KForm 4
Mar 9, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan29,871$30.02$897KForm 4
Mar 6, 2026Benjamin HohlCFOSale10,000$29.58$296KForm 4
Feb 17, 2026Richard A. HeymanDirectorSale plan1,230$26.18$32.2KForm 4
Feb 17, 2026Helen Louise CollinsCHIEF MEDICAL OFFICERSale plan45,000$26.17$1.2MForm 4
Feb 6, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan5,000$29.04$145KForm 4
Jan 20, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan14,509$26.90$390KForm 4
Jan 20, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan5,491$26.37$145KForm 4
Jan 20, 2026Richard A. HeymanDirectorSale plan512$26.46$13.5KForm 4
Jan 20, 2026Richard A. HeymanDirectorSale plan718$26.96$19.4KForm 4
Jan 9, 2026Anish PatelCHIEF OPERATING OFFICERSale plan243$28.50$6.9KForm 4
Jan 9, 2026Anish PatelCHIEF OPERATING OFFICERSale plan48,057$27.98$1.3MForm 4
Jan 9, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan41,198$24.90$1MForm 4
Jan 9, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan50,000$29.13$1.5MForm 4
Jan 9, 2026Richard A. HeymanDirectorSale plan4,285$25.00$107KForm 4
Jan 8, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan7,500$20.13$151KForm 4
Jan 8, 2026Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan33,802$24.92$842KForm 4
Jan 8, 2026Richard A. HeymanDirectorSale plan8,015$25.04$201KForm 4
Jan 8, 2026Richard A. HeymanDirectorSale plan1,620$25.00$40.5KForm 4
Dec 19, 2025Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan5,000$16.84$84.2KForm 4
Dec 8, 2025Anish PatelCHIEF OPERATING OFFICERSale plan4,958$20.76$103KForm 4
Dec 8, 2025Anish PatelCHIEF OPERATING OFFICERSale plan1,705$21.78$37.1KForm 4
Nov 19, 2025Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan12,008$22.30$268KForm 4
Nov 19, 2025Joseph P LyssikatosCHIEF SCIENTIFIC OFFICERSale plan492$23.09$11.4KForm 4
Nov 17, 2025Samuel KintzCEOSale plan12,500$21.82$273KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Orbimed Advisors Llc10% owner–$51.7MJun 22, 2026
Mika K DerynckDirector–$9.6MAug 4, 2026
Helen Louise CollinsCHIEF MEDICAL OFFICER–$5.6MOct 19, 2026
Joseph P LyssikatosCHIEF SCIENTIFIC OFFICER–$4.5MFeb 6, 2026
Benjamin HohlCHIEF FINANCIAL OFFICER–$1.8MOct 19, 2026
Anish PatelCHIEF OPERATING OFFICER–$1.5MJan 9, 2026
Lori Anne KunkelDirector–$850KJul 6, 2026
J. Scott GarlandDirector–$607KOct 1, 2026
Richard A. HeymanDirector–$413KFeb 17, 2026
Samuel KintzPRESIDENT AND CEO, Director–$273KNov 17, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ELVN short interest

High short interest. 14.0% of ELVN shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 101%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.29M ELVN shares were sold short, 14.0% of the shares outstanding, up 10.3% from the report before. At the average daily volume of 1.81M shares, buying them all back would take about 5.7 trading days (days to cover).

Shares short, % of all shares

14.0%May 15Oct 3015.1%

Days to cover

5.7May 15Oct 3012.8

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.29M13.99%+10%1.81M5.7
Oct 15, 20269.33M12.74%-10%1.25M7.5
Sep 30, 202610.36M14.13%+20%1.89M5.5
Sep 15, 20268.62M11.77%+0%956,4949.0
Aug 31, 20268.60M11.74%+4%776,60711.1
Aug 14, 20268.26M11.27%+1%1.30M6.3
Jul 31, 20268.15M11.13%-6%712,36711.4
Jul 15, 20268.65M14.21%+1%919,2729.4
Jun 30, 20268.53M14.00%+57%2.76M3.1
Jun 15, 20265.43M8.91%+4%2.08M2.6
May 29, 20265.21M8.56%+2%597,2688.7
May 15, 20265.12M8.41%-3%636,6868.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Enliven Therapeutics company events

Enliven Therapeutics filed 10 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 14, 2026LeadershipThe board of directors of Enliven Therapeutics, Inc. increased the size of the Board from seven to eight directors and appointed Kristine Ball to serve as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders, and as a member of the Audit Committee of the… Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jun 12, 2026AgreementEnliven Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Morgan Stanley & Co. LLC and Barclays Capital Inc. as representatives of the several underwriters named therein, relating to the issuance and sale in a public offering of 8,933,334 shares… Filing
  5. Jun 11, 2026AnnouncementThe Company announced updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with CML and key outcomes from the Company’s End-of-Phase 1 meeting with the U.S. Food and Drug Administration. Filing
  6. Jun 10, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Mar 3, 2026ResultsReleased financial results. Filing
  9. Jan 7, 2026LeadershipThe board of directors of Enliven Therapeutics, Inc. appointed Scott Garland to serve as a Class I director, with a term expiring at the Company’s 2027 annual meeting of stockholders, and as the Chair of the Nominating and Corporate Governance Committee of the Board, effective January 7, 2026. Filing
  10. Dec 11, 2025LeadershipEnliven Therapeutics, Inc. announced the appointment of Richard Fair as the Company’s President and Chief Executive Officer and as a member of the board of directors of the Company, effective as of December 11, 2025. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Enliven Therapeutics financials

Famous investors that hold ELVN

4 of the 50 well-known investors we track reported holding ELVN in their latest 13F filing. The largest position is Ken Griffin's, worth $57M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.24M$57M0.0%-40%
Israel Englander · Millennium ManagementQ3 2026493,615$22.6M0.0%+20%
Jim Simons · Renaissance TechnologiesQ3 2026170,735$7.8M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202613,601$623K0.0%-66%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ELVN in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Vestal Point Capital, LP13G/A4.4%
Nov 16, 2026Vestal Point Capital, LP13G/A4.4%
Oct 27, 2026BlackRock, Inc.13G/A7.1%
Oct 27, 2026BlackRock, Inc.13G/A7.1%

Questions about Enliven Therapeutics, Inc. (ELVN) stock

Who owns the most ELVN stock?

The largest reported owner of Enliven Therapeutics, Inc. (ELVN) is FMR LLC (Fidelity), with 16.5% of the company. In total, 211 funds and institutions reported holding ELVN at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are ELVN insiders buying or selling?

In the last 12 months, ELVN insiders reported no open-market purchases and 74 sales worth $76.7M. The latest trade was on Oct 19, 2026. See every trade.

What is the short interest in ELVN?

As of Oct 30, 2026, 10.29M ELVN shares were sold short, 14.0% of the shares outstanding, up 10.3% from the report before. At the average daily volume of 1.81M shares, buying them all back would take about 5.7 trading days (days to cover). See the history.

Which famous investors hold ELVN?

4 of the 50 well-known investors we track reported ELVN in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $57M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.